Cellectis (CLLS) SEC Filings & 10K Form $1.65 +0.10 (+6.45%) Closing price 03:59 PM EasternExtended Trading$1.56 -0.09 (-5.45%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent Cellectis SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel DateFilerForm TypeView06/26/20253:30 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 06/26/20253:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 05/21/20253:30 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 05/21/20253:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 05/06/20253:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 04/28/20253:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 03/13/20257:01 PMCellectis (Filer)Form 20-FRegistration statement / Annual report / Transition report 03/07/20253:39 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 02/24/20255:00 AMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 01/30/20258:36 PMBpifrance Participations SA (Filed by)Cellectis (Subject)Form SCHEDULE 13D/A01/24/20258:52 AMASTRAZENECA PLC (Filed by)ASTRAZENECA PLC (Filed by)Cellectis (Subject)Form SCHEDULE 13D/A Get the Latest News and Ratings for CLLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. 01/23/202511:15 PMCellectis (Filer)Form EFFECT01/15/20253:35 PMCellectis (Filer)Form F-3Registration statement for securities of certain foreign private issuers 01/15/20253:31 PMCellectis (Filer)Form S-8Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans 12/10/20243:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 11/05/20243:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 10/30/20243:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 10/22/20245:07 AMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 09/11/20243:30 PMCellectis (Filer)Form 6-K/A09/03/20243:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 08/26/20243:31 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 08/07/20245:00 AMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 08/06/20243:30 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 08/01/20243:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 07/25/20243:35 PMCellectis (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies Inventiva 10Q Form Astria Therapeutics 10Q Form Gossamer Bio 10Q Form Aura Biosciences 10Q Form Aardvark Therapeutics 10Q Form Olema Pharmaceuticals 10Q Form Aerovate Therapeutics 10Q Form Ocugen 10Q Form Monte Rosa Therapeutics 10Q Form Atea Pharmaceuticals 10Q Form SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:CLLS) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
